Net Income
Trailing-twelve-month (TTM) net income is $302.80 Million with a year-over-year change of (24.71%). Net income represents the company's bottom line profit after all expenses, taxes, and interest.
PODD Net Income
Reported quarterly net income; no daily interpolation.
PODD Quarterly Net Income Growth (YoY)
Net Income growth vs the same quarter one year earlier, last 20 quarters.
Net Income (TTM)
$302.80M
$302.80 Million
Year-over-Year Change
(24.71%)
vs. $402.18M a year ago (TTM)
Net Income CAGR
+99.86%
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
(24.71%)
3 Year
+695.79%
5 Year
+99.86%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $247.10M | ($171.20M) | (40.93%) |
| 2024 | $418.30M | +$212.00M | +102.76% |
| 2023 | $206.30M | +$201.70M | +4384.78% |
| 2022 | $4.60M | ($12.20M) | (72.62%) |
| 2021 | $16.80M | +$10.00M | +147.06% |
| 2020 | $6.80M | ($4.80M) | (41.38%) |
| 2019 | $11.60M | +$8.31M | +252.37% |
| 2018 | $3.29M | +$30.12M | — |
| 2017 | ($26.83M) | +$2.05M | — |
| 2016 | ($28.88M) | +$44.64M | — |
Net Income Growth Summary
TTM Growth
(24.71%)
3-Year Avg Growth
+695.79%
5-Year Avg Growth
+99.86%
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy